Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide and Skin Autofluorescence in Knee Osteoarthritis
NCT02910570Phase 4Completed
- Sponsor
- Parker Institute for Cancer Immunotherapy
- Start
- Nov 2016
- Primary completion
- Feb 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in obesity comparing Liraglutide 3 mg with Liraglutide 3 mg placebo (2 arms). Primary endpoint: Advanced glycation end products in the skin at 52 weeks. Started Nov 2016; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02910570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02910570.